Main Article Content

Faiza Inam
Rabia Ghafoor
Bahram Khan Khoso
Syeda Mahanum Ali
Parisa Sanawar
Khadija Asadullah


Outcome, Secukinumab, moderate to severe plaque psoriasis.


Objective: To determine the outcome of Secukinumab in the therapy of moderate to severe plaque psoriasis at a tertiary care hospital of Karachi, Pakistan.

Study design: Single arm non-randomized trial

Place and duration of study: Department of Dermatology, Jinnah Postgraduate Medical Centre, Karachi from 5th July 2021 to 10th July 2022.

Methodology: The study included moderate or severe plaque psoriasis patients aged 30 years or older receiving treatment with subcutaneous injections of Secukinumab 300mg at zero one two three and four weeks and then every  month for five months. Patients were followed till week 25. Pre and post therapy photographs were taken. Psoriasis Area and Severity Index (PASI) was calculated before and after treatment. Outcome was assessed in terms of improvement in plaque psoriasis. All patients who were presented with 75% decline in the PASI at the end of the therapy as compared to baseline were labelled as improvement.

Results: Of 35 patients, the average age was 37.68 ± 9.89 years, with a majority of 22 (65.7%) males. The average duration of psoriasis was 10.42 ± 8.03 years, and psoriatic arthritis was observed in 15 (42.9%) patients. The PASI score decreased from 20.66 ± 3.09 to 4.22 ± 1.66 (p-value < 0.001, 95% CI 15.50 to 17.36), representing an average reduction of 79.73%. The treatment showed >75% decrease in PASI score post-treatment in 31 (88.57%) patients. Adverse events were reported in 2 patients.

Conclusion: Current study findings showed a good outcome and established the safety of secunkinumab in therapy of patients with moderate to severe plaque psoriasis.

Abstract 182 | PDF Downloads 92


1. Pariser D, Frankel E, Schlessinger J, Poulin Y, Vender R, Langley RG et al. Efficacy of secukinumab in the treatment of moderate to severe plaque psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies. Dermatol Ther (Heidelb). 2018; 8(1):17-32.
2. Alexis AF, Blackcloud P. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014; 7:16–24.
3. Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol. 2014; 41:1039–46.
4. Asahina A, Torii H, Ohtsuki M, Tokimoto T, Hase H, Tsuchiya T, et al. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: results of SALSA study. J Dermatol. 2016; 43:1257–66.
5. Galica K, Lesiak A, Ciążyńska M, Noweta M, Bednarski I, Narbutt J. Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study. Postepy Dermatol Alergol. 2021; 38(6):973-78.
6. Shaukat S, Khan S, Hussain I. IL-17 and its role in psoriasis. J Pak Assoc Dermatol. 2017; 27 (1):1-3.
7. Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8.
8. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014; 371(4):326-38. doi: 10.1056/NEJMoa1314258.
9. Tariq H, Basharat M, Javed S, Aman S. Efficacy and safety of secukinumab in treatment of moderate to severe psoriasis. J Pak Ass Derm 2022; 32(1):9-14
10. Tirmizi SS. Efficacy of Secukinumab in Moderate to Severe Psoriasis Vulgaris: A Prospective Study. Pak J Med Health Sci. 2022; 16(09):983-6.
11. Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013; 168(2):412-21. doi: 10.1111/bjd.12110.
12. Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013; 168(2):402-11. doi: 10.1111/bjd.12112.
13. Foley P, Spelman L, Murrell DF, Mate E, Tronnberg R, Lowe PM. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study. Australas J Dermatol. 2022; 63(3):312-20. doi: 10.1111/ajd.13893.
14. Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, et al. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results. J Eur Acad Dermatol Venereol. 2021; 35(2):431-40. doi: 10.1111/jdv.16632.
15. Blair HA. Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis. Paediatr Drugs. 2021 Nov;23(6):601-608. doi: 10.1007/s40272-021-00476-w. Epub 2021. Erratum in: Paediatr Drugs. 2022; 24(1):91.
16. Jankowiak B, Kowalewska B, Krajewska-Kułak E, Khvorik DF. Stigmatization and Quality of Life in Patients with Psoriasis. Dermatol Ther (Heidelb). 2020; 10(2):285-296. doi: 10.1007/s13555-020-00363-1.
17. Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. Dermatology. 2006; 212(2):123-7. doi: 10.1159/000090652.
18. Homayoon D, Hiebler-Ragger M, Zenker M, Weger W, Unterrainer H, Aberer E. Relationship Between Skin Shame, Psychological Distress and Quality of Life in Patients with Psoriasis: a Pilot Study. Acta Derm Venereol. 2020; 100(14):adv00205. doi: 10.2340/00015555-3563.
19. Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, et al. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Treat. 2017; 28(6):492-9. doi: 10.1080/09546634.2017.1294727. Epub 2017 Mar 7. Erratum in: J Dermatolog Treat. 2017; 28(6):571.
20. Bardowska K, Krajewski PK, Tyczyńska K, Szepietowski JC. Safety evaluation of secukinumab in pediatric patients with plaque psoriasis. Expert Opin Drug Saf. 2022; 21(7):867-72. doi: 10.1080/14740338.2022.2073349.

Most read articles by the same author(s)